Guardant Health, Inc. current report, 04 April 2023

Guardant Health, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Guardant Health, Inc. on April 4, 2023. The report discloses a change in the Company's independent registered public accounting firm.

Financial Metrics

The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the change in auditors.

Material Changes

  • Accountant Change: The Audit Committee approved the engagement of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2023.
  • Dismissal: Ernst & Young LLP was dismissed as the independent registered public accounting firm, effective immediately.
  • Audit History: Ernst & Young's audit reports for the fiscal years ended December 31, 2022, and 2021, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
  • Disagreements: There were no disagreements between the Company and Ernst & Young on accounting principles, practices, financial statement disclosure, or auditing scope/procedure during the relevant periods.
  • Reportable Events: No "reportable events" occurred during the fiscal years ended December 31, 2022 and 2021, or the subsequent interim period through April 4, 2023.

Guidance, Outlook, and Risks

The filing does not contain management guidance, outlook, or specific risk factors related to financial performance. The primary disclosure is the procedural change in audit oversight. The Company confirmed that no consultations with Deloitte regarding accounting principles or audit opinions occurred prior to the engagement.

Key Facts for Investor Verification

  • Verify the effective date of the transition from Ernst & Young to Deloitte & Touche LLP.
  • Confirm the absence of any undisclosed disagreements or reportable events with the former auditor.
  • Review the letter from Ernst & Young LLP (Exhibit 16.1) to ensure they agree with the statements made in this filing.
  • Monitor future filings for the first financial statements audited by Deloitte & Touche LLP.